This story has been updated with new information from a letter released today from Origin Technologies to Affymetrix demonstrating an increased financing committment and adressing other concerns.

NEW YORK (GenomeWeb) – An offer by former Affymetrix executives to buy the company under a newly formed shell corporation — and to pay off the cancellation penalties of Thermo Fisher Scientific's previously announced proposal to acquire Affy — has triggered a call and response between Affy, Thermo, and the newcomer Origin Technologies this week.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.